High-dose azathioprine in children with inflammatory bowel disease

Alimentary Pharmacology and Therapeutics

Volumn 17, Issue 7, 2003, Pages 913-921

  Fuentes, D ^a   Torrente, F ^a,b   Keady, S ^a   Thirrupathy, K ^a   Thomson, M A ^a   Walker Smith, J A ^a   Murch, S H ^a   Heuschkel, R B ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b G GASLINI INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE;

ADOLESCENT; ARTICLE; BODY HEIGHT; BODY WEIGHT; BONE MARROW TOXICITY; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; CROHN DISEASE; DRUG MEGADOSE; ENTERITIS; FOLLOW UP; HUMAN; INTESTINE SURGERY; MAJOR CLINICAL STUDY; OUTCOMES RESEARCH; PRIORITY JOURNAL; RECURRENT INFECTION; RETROSPECTIVE STUDY; STANDARDIZATION; TREATMENT OUTCOME; VIRUS INFECTION;

ADMINISTRATION, ORAL; ADOLESCENT; AZATHIOPRINE; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FOLLOW-UP STUDIES; GROWTH; HUMANS; INFANT; INFLAMMATORY BOWEL DISEASES; LOGISTIC MODELS; RETROSPECTIVE STUDIES;

EID: 0037392264     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2003.01540.x     Document Type: Article

References (40)

1. Sawczenko A, Sandhu BK, Logan RE, et al. Prospective survey of childhood inflammatory bowel disease in the British Isles. Lancet 2001; 357: 1093-4.
2. Pearson DC, May GR, Fick G, Sutherland LR. Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst Rev 2000; AD: CD000067.
3. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002; 50: 485-9.
4. D'Haens G, Geboes K, Ponette E, Penninckx F, Rutgeerts P. Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease. Gastroenterology 1997; 112: 1475-81.
5. Connell WR. Kamm MA, Ritchie JK, Lennard-Jones JE. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993; 34: 1081-5.
6. Kirschner BS. Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology 1998; 115: 813-21.
7. Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn's disease. A meta-analysis. Ann Intern Med 1995; 123: 132-42.
8. Markowitz J, Grancher K, Mandel F, Daum F. Immunosuppressive therapy in pediatric inflammatory bowel disease: results of a survey of the North American Society for Pediatric Gastroenterology and Nutrition. Subcommittee on Immunosuppressive Use of the Pediatric IBD Collaborative Research Forum. Am J Gastroenterol 1993; 88: 44-8.
9. Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 1980; 302: 981-7.
10. Sandborn WJ, Tremaine WJ, Wolf DC, et al. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group, Gastroenterology 1999; 117: 527-35.
11. Casson DH, Davies SE, Thomson MA, Lewis A, Walker-Smith JA, Murch SH. Low-dose intravenous azathioprine may be effective in the management of acute fulminant colitis complicating inflammatory bowel disease. Aliment Pharmacol Ther 1999; 13: 891-5.
12. Sandborn WJ, Van OE, Zins BJ, Tremaine WJ, Mays DC, Lipsky JJ. An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's disease. Gastroenterology 1995; 109: 1808-17.
13. Crawford DJ, Maddocks JL, Jones DN, Szawlowski P. Rational design of novel immunosuppressive drugs: analogues of azathioprine lacking the 6-mercaptopurine substituent retain or have enhanced immunosuppressive effects. J Med Chem 1996; 39: 2690-5.
14. Cuffari C, Theoret Y, Latour S, Seidman G. 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. Gut 1996; 39: 401-6.
15. Gupta P, Gokhale R, Kirschner BS. 6-mercaptopurine metabolite levels in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2001; 33: 450-4.
16. Lowry PW, Franklin CL, Weaver AL, et al. Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut 2001; 49: 665-70.
17. Dubinsky MC, Yang H, Hassard PV, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002; 122: 904-15.
18. Walker-Smith JA. Management of growth failure in Crohn's disease. Arch Dis Child 1996; 75: 351-4.
19. Ouinn MA, Conaghan PG, Emery P. The therapeutic approach of early intervention for rheumatoid arthritis: what is the evidence? Rheumatology (Oxford) 2001; 40: 1211-20.
20. Markowitz J, Grancher K, Kohn N, Lesser M, Daum F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000; 119: 895-902.
21. Fell JM, Paintin M, Arnaud-Battandier F, et al. Mucosal healing and a fall in mucosal pro-inflammatory cytokine mRNA induced by a specific oral polymeric diet in paediatric Crohn's disease. Aliment Pharmacol Ther 2000; 14: 281-9.
22. Hildebrand H, Aronson S, Selvik G. Growth as a parameter of inflammation in Crohn's disease, using roentgen stereophotogrammetric analysis. Acta Paediatr 1994; 83: 1070-5.
23. Waterlow JC, Buzina R, Keller W, Lane JM, Nichaman MZ, Tanner JM. The presentation and use of height and weight data for comparing the nutritional status of groups of children under the age of 10 years. Bull World Health Organ 1977; 55: 489-98.
24. Beattie RM, Schiffrin EJ, Donnet-Elughes A, et al. Polymeric nutrition as the primary therapy in children with small bowel Crohn's disease. Aliment Pharmacol Ther 1994; 8: 609-15.
25. Hyams JS, Ferry GD, Mandel FS, et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr 1991; 12: 439-47.
26. Griffiths AM, Nguyen P, Smith C, MacMillan JH, Sherman PM. Growth and clinical course of children with Crohn's disease. Gut 1993; 34: 939-43.
27. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118: 705-13.
28. Anstey A, Lennard L, Mayou SC, Kirby JD. Pancytopenia related to azathioprine - an enzyme deficiency caused by a common genetic polymorphism: a review. J R Soc Med 1992; 85: 752-6.
29. Rosen R, Integlia MJ, Bousvaros A. Severe pancytopenia from thiopurine methyltransferase deficiency: a preventable complication of 6-mercaptopurine therapy in children with Crohn's disease. J Pediatr Gastroenterol Nutr 2002; 35: 695-9.
30. Markowitz J, Grancher K, Rosa J, Aiges H, Daum F. Growth failure in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1993; 16: 373-80.
31. Kanof ME, Lake AM, Bayless TM. Decreased height velocity in children and adolescents before the diagnosis of Crohn's disease. Gastroenterology 1988; 95: 1523-7.
32. Motil KJ, Grand RJ, Davis-Kraft L, Ferlic LL, Smith EO. Growth failure in children with inflammatory bowel disease: a prospective study. Gastroenterology 1993; 105: 681-91.
33. Spray C, Debelle GD, Murphy MS. Current diagnosis, management and morbidity in paediatric inflammatory bowel disease. Acta Paediatr 2001; 90: 400-5.
34. Markowitz J, Daum F. Growth impairment in pediatric inflammatory bowel disease. Am J Gastroenterol 1994; 89: 319-26.
35. Sanderson IR, Udeen S, Davies PS, Savage MO, Walker-Smith JA. Remission induced by an elemental diet in small bowel Crohn's disease. Arch Dis Child 1987; 62: 123-7.
36. Murch SH. Local and systemic effects of macrophage cytokines in intestinal inflammation. Nutrition 1998; 14: 780-3.
37. Koniaris SG, Fisher SE, Rubin CT, Chawla A. Experimental colitis impairs linear bone growth independent of nutritional factors. J Pediatr Gastroenterol Nutr 1997; 25: 137-41.
38. De Benedetti F, Alonzi T, Moretta A, et al. Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation. J Clin Invest 1997; 99: 643-50.
39. Braegger CP, Nicholls S, Murch SH, Stephens S, MacDonald TT, Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992; 339: 89-91.
40. Azcue M, Rashid M, Griffiths A, Pencharz PB. Energy expenditure and body composition in children with Crohn's disease: effect of enteral nutrition and treatment with prednisolone. Gut 1997; 41: 203-8.